These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 11544571)

  • 1. Studies in Paget's disease and their relevance to oncology.
    Roodman GD
    Semin Oncol; 2001 Aug; 28(4 Suppl 11):15-21. PubMed ID: 11544571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget's disease of bone.
    Menaa C; Reddy SV; Kurihara N; Maeda H; Anderson D; Cundy T; Cornish J; Singer FR; Bruder JM; Roodman GD
    J Clin Invest; 2000 Jun; 105(12):1833-8. PubMed ID: 10862799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates.
    Alvarez L; Peris P; Guañabens N; Vidal S; Ros I; Pons F; Filella X; Monegal A; Muñoz-Gomez J; Ballesta AM
    Arthritis Rheum; 2003 Mar; 48(3):824-8. PubMed ID: 12632438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteoclast differentiation from circulating mononuclear precursors in Paget's disease is hypersensitive to 1,25-dihydroxyvitamin D(3) and RANKL.
    Neale SD; Smith R; Wass JA; Athanasou NA
    Bone; 2000 Sep; 27(3):409-16. PubMed ID: 10962353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone stromal cells in pagetic bone and Paget's sarcoma express RANKL and support human osteoclast formation.
    Sun SG; Lau YS; Itonaga I; Sabokbar A; Athanasou NA
    J Pathol; 2006 May; 209(1):114-20. PubMed ID: 16482498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased IL-6 expression in osteoclasts is necessary but not sufficient for the development of Paget's disease of bone.
    Teramachi J; Zhou H; Subler MA; Kitagawa Y; Galson DL; Dempster DW; Windle JJ; Kurihara N; Roodman GD
    J Bone Miner Res; 2014 Jun; 29(6):1456-65. PubMed ID: 24339057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteoclast function in Paget's disease and multiple myeloma.
    Roodman GD
    Bone; 1995 Aug; 17(2 Suppl):57S-61S. PubMed ID: 8579899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of serum cytokines and growth factors on osteoclast formation in Paget's disease.
    Neale SD; Schulze E; Smith R; Athanasou NA
    QJM; 2002 Apr; 95(4):233-40. PubMed ID: 11937650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteoclasts formed by measles virus-infected osteoclast precursors from hCD46 transgenic mice express characteristics of pagetic osteoclasts.
    Reddy SV; Kurihara N; Menaa C; Landucci G; Forthal D; Koop BA; Windle JJ; Roodman GD
    Endocrinology; 2001 Jul; 142(7):2898-905. PubMed ID: 11416009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p62 ubiquitin binding-associated domain mediated the receptor activator of nuclear factor-kappaB ligand-induced osteoclast formation: a new insight into the pathogenesis of Paget's disease of bone.
    Yip KH; Feng H; Pavlos NJ; Zheng MH; Xu J
    Am J Pathol; 2006 Aug; 169(2):503-14. PubMed ID: 16877352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell biology of Paget's disease.
    Reddy SV; Menaa C; Singer FR; Demulder A; Roodman GD
    J Bone Miner Res; 1999 Oct; 14 Suppl 2():3-8. PubMed ID: 10510206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteocytes and Paget's Disease of Bone.
    Tenshin H; Delgado-Calle J; Windle JJ; Roodman GD; Chirgwin JM; Kurihara N
    Curr Osteoporos Rep; 2024 Apr; 22(2):266-272. PubMed ID: 38457001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteoclasts expressing the measles virus nucleocapsid gene display a pagetic phenotype.
    Kurihara N; Reddy SV; Menaa C; Anderson D; Roodman GD
    J Clin Invest; 2000 Mar; 105(5):607-14. PubMed ID: 10712432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A SQSTM1/p62 mutation linked to Paget's disease increases the osteoclastogenic potential of the bone microenvironment.
    Hiruma Y; Kurihara N; Subler MA; Zhou H; Boykin CS; Zhang H; Ishizuka S; Dempster DW; Roodman GD; Windle JJ
    Hum Mol Genet; 2008 Dec; 17(23):3708-19. PubMed ID: 18765443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenesis of Paget's disease of bone.
    Ralston SH
    Bone; 2008 Nov; 43(5):819-25. PubMed ID: 18672105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of immune cells and inflammatory cytokines in Paget's disease and multiple myeloma.
    Ehrlich LA; Roodman GD
    Immunol Rev; 2005 Dec; 208():252-66. PubMed ID: 16313353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paget's disease-a VDR coactivator disease?
    Kurihara N; Ishizuka S; Demulder A; Menaa C; Roodman GD
    J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):321-5. PubMed ID: 15225793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel mutation (K378X) in the sequestosome 1 gene associated with increased NF-kappaB signaling and Paget's disease of bone with a severe phenotype.
    Rea SL; Walsh JP; Ward L; Yip K; Ward BK; Kent GN; Steer JH; Xu J; Ratajczak T
    J Bone Miner Res; 2006 Jul; 21(7):1136-45. PubMed ID: 16813535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased S1P expression in osteoclasts enhances bone formation in an animal model of Paget's disease.
    Nagata Y; Miyagawa K; Ohata Y; Petrusca DN; Pagnotti GM; Mohammad KS; Guise TA; Windle JJ; David Roodman G; Kurihara N
    J Cell Biochem; 2021 Apr; 122(3-4):335-348. PubMed ID: 33107091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experimental models of Paget's disease.
    Kurihara N; Zhou H; Reddy SV; Garcia Palacios V; Subler MA; Dempster DW; Windle JJ; Roodman GD
    J Bone Miner Res; 2006 Dec; 21 Suppl 2():P55-7. PubMed ID: 17229020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.